Related Experiment Videos
Nuclear oncology and the Imagene concept
J L Urbain1, M C Vekemans, S K Lemieux
1Department of Diagnostic Imaging, Temple University School of Medicine, Philadelphia, PA, USA. jlurbain@astro.ocis.temple.edu
Acta Radiologica. Supplementum
|January 1, 1997
Summary
Nuclear oncology has rapidly advanced with new radioisotopic tracers for tumor detection, staging, and treatment. Future molecular probes will offer even greater specificity in cancer diagnosis and therapy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Significant advancements in radioisotopic tracers over the past two decades.
- Nuclear oncology has emerged as a distinct medical specialty.
- Evolution from non-specific tracers (e.g., thallium 201, gallium 67) to targeted agents.
Purpose of the Study:
- To review recent developments in nuclear oncology.
- To highlight the expanding range of radioisotopic tracers available.
- To discuss the future potential of molecular probes in cancer care.
Main Methods:
- Review of current and emerging radioisotopic tracers.
- Discussion of radiolabeled monoclonal antibodies and metabolic tracers.
- Exploration of potential molecular probes derived from genomic sequencing.
Main Results:
- Availability of specific radiolabeled monoclonal antibodies and metabolic tracers.
- Anticipation of highly specific molecular probes based on human genome sequencing.
- Demonstration of nuclear oncology's growth and increasing clinical utility.
Conclusions:
- Nuclear oncology offers powerful tools for tumor detection, staging, and treatment.
- Ongoing innovation promises more precise and personalized cancer diagnostics and therapeutics.
- The field is rapidly evolving, integrating advanced molecular biology with nuclear imaging and therapy.